Age Related Macular Degeneration
Conditions
Keywords
macular degeneration, angiogenesis, antibodies
Brief summary
The purpose of this study is to determine whether intravitreal injection of bevacizumab is effective in the treatment of neovascular age related macular degeneration
Detailed description
The neovascular age related macular degeneration(AMD) is a important cause of legal blindness in adults older than 50 years. Currently the treatment is photodynamic therapy that offer stabilization and limited visual improvement after 2 years of therapy. Bevacizumab has been reported effective used as intravenous injection for AMD. But serious side effects have been reported with the use of this drug in oncologic patients. The intravitreal use has been reported in limited case reports and safety and efficacy should be determined. The purpose of this study is efficacy and safety of 2.5 mg intravitreal of bevacizumab for AMD
Interventions
Sponsors
Asociación para Evitar la Ceguera en México
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* age \>50 age related macular degeneration
Exclusion criteria
* moderate to severe cataract glaucoma intraocular surgery diabetes mellitus non controlled hypertension coronary artery disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of visual acuity at 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Retinal thickness at 6 months | — |
| Leakiness in fluorangiography at 6 months | — |
Countries
Mexico
Outcome results
None listed